Protocadherin 10 (PCDH10) Kits ELISA

Human Protocadherin 10 (PCDH10) interaction partners

1. Study found elevated promoter methylation and decreased expression of PCDH10 and PCDH17 in advanced gastric lesions, suggesting that elevated PCDH10 and PCDH17 methylation may be an early event in gastric carcinogenesis.

2. Study shows for that the methylation status of PCDH10 can predict prognosis in pancreatic ductal adenocarcinoma (PDAC) patients with a significant impact on the outcome in terms of progression-free survival. High levels of PCDH10 promoter methylation could be useful to identify patients at high risk of PDAC disease progression.

3. PCDH10 hypermethylation were found in 54.2% (58/107) of DLBCL cases, but only 12.5% (1/8) in reactive lymph node/follicular hyperplasia.

4. This study provides insights into the tumorigenesis and progression of hepatocellular carcinoma (HCC), and puts forward the novel hypothesis that PCDH10 could be a new biomarker for HCC, or that combined with other molecular markers could increase the specificity and sensitivity of diagnostic tests for HCC. Restoration of PCDH10 could be a valuable therapeutic target for HCC.

5. we found that the malignant character of GISTs was initiated and amplified by PCDH10 in a process regulated by HOTAIR. In summary, our findings imply that PCDH10 and HOTAIR may be useful markers of disease progression and therapeutic targets.

6. we found that long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion

7. These findings suggest that Pcdh10 may influence subcellular actin cytoskeletal organization and axon-axon interactions in the course of familial amyloidotic polyneuropathy

8. PCDH10 methylation in serum is a potential prognostic biomarker for prostate cancer.

9. Study found that hypermethylation of CpG probes in the promoter regions of HOXA9 and PCDH10 was associated with mature B-cell neoplasms.

10. Results suggest that protocadherin 10 (PCDH10)-Dishevelled, EGL-10 and Pleckstrin domain containing 1 (DEPDC1)-caspase signaling may be a novel regulatory axis in endometrial endometrioid carcinoma (EEC) development.

11. Data show that protocadherin 10 (PCDH10) over-expression could significantly induce cell apoptosis, and restrain proliferation, invasion and migration ability of BXPC-3 pancreatic cancer cells.

12. Our present findings suggested that the hypermethylated CpG site counts of PCDH10 DNA promoter for evaluating the prognosis of GC was reasonable by using the D-BGS

13. PCDH10 methylation is a potential biomarker that predicts a poor prognosis after curative resection of pathological stage I non-small-cell lung cancer.

14. PCDH10 antagonized MM cell proliferation via the downregulation of Wnt/beta-catenin/BCL-9 signaling, whereas PCDH10 repressed the expression of AKT to promote the expression of GSK3beta and then to restrain the activation of beta-catenin

15. These results suggest an important role of p53 in regulating tumor cell migration through activating PCDH10 expression.

16. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.

17. Gastric cancer patients with 5 or more methylated CpG sites of PCDH10 promoter had significantly poorer survival.

18. Findings establish a novel PCDH10-Wnt/beta-catenin-MALAT1 regulatory axis that contributes to EEC development.

19. These results indicate that promoter methylation status of PCDH10, SPARC, and UCHL1 may be used both as prognostic and predictive molecular marker for colorectal cancer patients

20. Loss of PCDH10 expression is associated with metastasis in colorectal cancer.

Mouse (Murine) Protocadherin 10 (PCDH10) interaction partners

1. Olivocerebellar and corticonuclear axonal labeling confirmed that the three cortical pcdh10-positive areas were topographically connected to the nuclear and olivary pcdh10-positive areas, demonstrating their coincidence with modular structures in the olivo-cortico-nuclear loop

2. Comparative semi-quantitative Pcdh 10 immunohistochemistry of the brains of human V30M transgenics did not show significant staining as peripheral nerve did, emphasizing the specificity of Pcdh 10 in peripheral nerve of amyloidogenic V30M transgenics.

3. male Pcdh10(+/-) mice exhibited reduced gamma-band (30-80Hz), but not lower frequency (10 and 20Hz), auditory steady state responses (ASSR). In addition, male Pcdh10(+/-) mice exhibited decreased signal-to-noise-ratio (SNR) for high gamma-band (60-100Hz) activity. Administration of a GABAB agonist remediated these electrophysiological alterations among male Pcdh10(+/-)mice.

4. Studies reveals that male Pcdh10(+/-) mice have synaptic and behavioral deficits, and establish Pcdh10(+/-) mice as a novel genetic model for investigating neural circuitry and behavioral changes relevant to autism spectrum disorder.

5. Pcdh10, which is regulated by Pou3f1 and Hoxa5, is a mediator of like-like clustering of motor neuron cell bodies in the developing phrenic nerve.

6. results show that OL-pc is essential for both elongation of striatal axons and patterning of the putative guidance cues for thalamocortical projections.

7. The role of OL-protocadherin-dependent striatal axon growth in neural circuit formation.